Menü Schließen

Wie erfolgreich ist Immuntherapie?

Wie erfolgreich ist Immuntherapie?

Wie Studien ergaben, kann der Einsatz von Checkpoint-Inhibitoren große Erfolge bei verschiedenen Krebsarten erzielen, jedoch spricht nur ein kleiner Anteil (ca. 20-30 Prozent über verschiedene Entitäten hinweg) der Patienten auf diese Therapien an.

Wie lange Nebenwirkungen nach Immuntherapie?

Die meisten Nebenwirkungen treten innerhalb von 3–6 Monaten nach Beginn der Immuntherapie auf. Einige immunvermittelte Nebenwirkungen manifestieren sich aber erst große Zeit später, bis zu mehreren Jahren, nach der Verabreichung.

What are the treatment options for a cholangiocarcinoma recurrence?

Treatment for a cholangiocarcinoma recurrence may include surgery, chemotherapy or radiation therapy. The recommended approach can vary based on a number of factors, including the location of the cancer, the cancer’s response to the initial treatment and the patient’s overall health condition.

What is the pathophysiology of cholangiocarcinoma?

Cholangiocarcinoma is a group of cancers that begin in the bile ducts. Bile ducts are branched tubes that connect the liver and gallbladder to the small intestine. They carry bile, which is a fluid that helps the body digest fats that are in food.

LESEN SIE AUCH:   Was ist der Labrador Retriever?

Does cholangiocarcinoma (bile duct cancer) recur?

Cholangiocarcinoma (Bile Duct Cancer) Recurrence. Cholangiocarcinoma recurrence is possible after a patient completes an initial course of treatment and is found to be cancer-free (in remission) for a period of time. For this reason, many experts recommend a carefully planned follow-up program, including regular physical examinations,…

What is perihilar Cholangiocarcinoma (Klatskin tumor)?

Perihilar cholangiocarcinoma (also known as a Klatskin tumor) begins in an area called the hilum, where the right and left major bile ducts join and leave the liver. It is the most common form of the disease, accounting for more than half of all cases.

https://www.youtube.com/watch?v=aUzumGra7eo